Navigation Links
£3m drug safety center investment
Date:1/29/2014

LIVERPOOL, UK 29 January 2014: The Medical Research Council (MRC) Centre for Drug Safety Science at the University of Liverpool has received three million pounds of new funding from MRC to allow it to continue reducing the impact of adverse reactions to medicinal drugs.

Adverse drug reactions result in one in 15 hospital admissions and cost the NHS in excess of 650 million every year. They are also a significant cause of drug attrition for the pharmaceutical industry. The Centre addresses these problems by gaining an understanding of the fundamental mechanisms that drive adverse drug reactions to improve patient care.

The new funding will allow the Centre to consolidate its main areas of research on drug-induced liver injury and drug-induced skin hypersensitivity, for which it is internationally renowned. The funding will also enable the development of new expertise in the significant clinical problem of gastrointestinal drug toxicity.

Training is a significant part of the Centre's mission and the funding will allow it to continue to train the next generation of clinical and non-clinical drug safety scientists to bridge the skills gap in this area for pharmaceutical companies, the biotechnology sector, contract research organisations and academia.

The Centre works alongside partners from academia, regulatory authorities and industry and has attracted over 16 million in additional funding since it was set up in 2008.

Professor Kevin Park, Director of the Centre said: "This is good news for the University of Liverpool and highlights the value that the MRC sees in our national centre of excellence. It is also good news for the people who are affected by adverse reactions to medicines".

Professor Munir Pirmohamed, Head of Department of Pharmacology said: "This highlights the critical mass of expertise we have in drug safety in Liverpool. The new funding and new equipment will allow us to continue to train scientists and clinicians and translate our research into both medical practice and drug development processes. Ultimately we want to make drugs much safer for everybody."

Dr Nathan Richardson, Head of Molecular and Cellular Medicine, MRC said: "The Centre has built up an impressive bio-analytical and training facility in the first five years of core funding, with partnerships between academics, clinicians, industry and regulatory authorities.

"Positioned as a key part of MRC's portfolio in drug safety science research, we are delighted to continue strategic support for the Centre, and look forward to seeing increasing impact of its research in clinical care, including through the new research area of gastrointestinal toxicity."


'/>"/>

Contact: Jamie Brown
jamie.brown@liverpool.ac.uk
44-151-794-2248
University of Liverpool
Source:Eurekalert

Related biology news :

1. Scientists awarded £3M to study the way Northwest European seas absorb carbon
2. Aspartame passes stiff review by European Food Safety Authority
3. Safety in numbers? Not so for corals
4. Duke wins $15 million renewal to study nanotech safety
5. UH among Texas institutions that will lead Ocean Energy Safety Institute
6. Findings announced from landmark study on safety of adolescent bariatric surgery
7. Reassuring findings released in national study of influenza vaccine safety in pregnancy
8. Seafood still considered a good source of nutrients but consumers confused on safety
9. RNA-interference pesticides will need special safety testing
10. Revolutionary Face Recognition Media Exploitation System Now Available to Enhance Public Safety in Europe
11. Additional research must be done to ensure safety of pit latrines, new study says
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... ALBANY, New York , April 19, 2017 /PRNewswire/ ... highly competitive, as its vendor landscape is marked by ... in the market is however held by five major ... and Safran. Together these companies accounted for nearly 61% ... majority of the leading companies in the global military ...
(Date:4/11/2017)... BEACH GARDENS, Fla. , April 11, 2017 ... identity management and secure authentication solutions, today announced ... contract by Intelligence Advanced Research Projects Activity (IARPA) ... for IARPA,s Thor program. "Innovation has ... onset and IARPA,s Thor program will allow us ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute for ... Cell Explorer: a one-of-a-kind portal and dynamic digital window ... imaging data, the first application of deep learning to ... stem cell lines and a growing suite of powerful ... for these and future publicly available resources created and ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... Palo Alto, CA, USA (PRWEB) , ... October 11, 2017 , ... ... is set to take place on 7th and 8th June 2018 in San Francisco, ... and policy influencers as well as several distinguished CEOs, board directors and government officials ...
(Date:10/11/2017)... ... October 11, 2017 , ... A ... pregnancy rates in frozen and fresh in vitro fertilization (IVF) transfer ... age to IVF success. , After comparing the results from the fresh and ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and CEO of ... Rotary Club. The event entitled “Stem Cells and Their Regenerative Powers,” ... Dr. Harman, DVM, MPVM was joined by two human doctors: Peter B. Hanson, ...
(Date:10/9/2017)... 9, 2017  BioTech Holdings announced today identification ... its ProCell stem cell therapy prevents limb loss ... Company, demonstrated that treatment with ProCell resulted in ... as compared to standard bone marrow stem cell ... in reduction of therapeutic effect.  ...
Breaking Biology Technology: